Original Publication Date: 1 June, 2014
Publication / Source: Future Oncology
Authors: Ichiro Nakano
Each year, more than 1.6 million people in the USA are diagnosed with new cancers, and this number has been continuously increasing for decades. Most of the targeted therapeutics tested thus far have shown little or limited sustained survival benefit. The failure to achieve a cure may include the presence of self-renewing, highly tumorigenic cancer stem cells (CSCs) contributing to therapeutic resistance and invasion into normal tissues. Targeting CSCs is probably mandated to inhibit tumor growth and sensitize tumors to conventional therapies. In a tumor mass, however, CSCs are tightly associated with other cells including non-CSCs and stromal cells.